UNSPSC 51273925: Bupivacaine/epinephrine/lidocaine/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273925 Bupivacaine/epinephrine/lidocaine/sodium chloride is a Commodity code for local anesthetic pharmaceutical compounds used in medical and emergency settings. The recent solicitation activity under this code does not reflect the narrow pharmaceutical scope of the code itself; instead, Seminole County, Florida issued an IFB for naloxone and drug deactivation systems—products outside the code's stated pharmaceutical compound family—suggesting either a tagging mismatch in the county's procurement system or a broader categorization encompassing emergency medical supplies beyond the specific local anesthetics named in the code. The work being solicited represents emergency response and community health support, with vendors required to provide pharmaceutical products and related systems on a fixed-fee basis with compliance obligations including drug-free workplace certification, E-Verify, workers' compensation insurance, and federal compliance (Clean Air Act, Federal Water Pollution Control Act) given potential FEMA funding.

Seminole County, Florida represents the only recent sourcing activity visible under this code. The county issued IFB 60459723LAS on June 30, 2026, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023 (note: the posted date and due date appear inconsistent in the source). The contract structure includes an initial two-year term with a one-year renewal option, electronic bidding through the county's e-Procurement Portal, and vendor responsibility for all shipping and delivery costs. The procurement does not specify explicit set-aside designations. Given the mismatch between the code's nominal scope and the actual products solicited, this code shows little relevant recent activity aligned with its stated pharmaceutical compound definition.